TY - JOUR
T1 - Combination of SVI/S′ and diagnostic scores for heart failure with preserved ejection fraction
AU - Mu, Guanyu
AU - Wang, Weiding
AU - Liu, Changle
AU - Xie, Juan
AU - Zhang, Hao
AU - Zhang, Xiaowei
AU - Che, Jingjin
AU - Tse, Gary
AU - Liu, Tong
AU - Li, Guangping
AU - Fu, Huaying
AU - Chen, Kangyin
N1 - Publisher Copyright:
© 2023 John Wiley & Sons Australia, Ltd.
PY - 2023/8
Y1 - 2023/8
N2 - The diagnosis of heart failure with preserved ejection fraction (HFpEF) remains a challenge. There are three methods proposed as diagnostic tools. H2FPEF score was determined by six weighted clinical characteristics and echocardiographic variables. Heart Failure Association (HFA)-PEFF algorithm consists of various functional and morphological variables as well as natriuretic peptides. SVI/S′ is a novel echocardiographic parameter calculated by stroke volume index and mitral annulus systolic peak velocity. This study aimed to compare the three approaches in patients with suspected HFpEF. Patients referred to right heart catheterization for suspected HFpEF were classified into low-, intermediate- and high-likelihood groups according to H2FPEF or HFA-PEFF scores. A diagnosis of HFpEF was confirmed by pulmonary capillary wedge pressure (PCWP) of ≥15 mm Hg according to the guidelines. In result, a total of 128 patients were included. Of these, 71 patients with PCWP ≥15 mm Hg and 57 patients with PCWP <15 mm Hg. Moderate correlations were observed between H2FPEF score, HFA-PEFF score, SVI/S′ and PCWP. The area under curve of SVI/S′ was 0.82 for diagnosis of HFpEF, compared with 0.67 for H2FPEF score and 0.75 for HFA-PEFF score by receiver-operating characteristics analysis. Combining SVI/S′ with diagnostic scores showed higher Youden index and accuracy than each score alone. Kaplan–Meier analysis reported that the high-likelihood group showed poorer outcomes regardless the method used for diagnosis. Among the contemporary tools for identifying HFpEF in this study, the combination of SVI/S′ with risk scores showed best diagnostic ability. Each of the strategies can determine rehospitalisation because of heart failure.
AB - The diagnosis of heart failure with preserved ejection fraction (HFpEF) remains a challenge. There are three methods proposed as diagnostic tools. H2FPEF score was determined by six weighted clinical characteristics and echocardiographic variables. Heart Failure Association (HFA)-PEFF algorithm consists of various functional and morphological variables as well as natriuretic peptides. SVI/S′ is a novel echocardiographic parameter calculated by stroke volume index and mitral annulus systolic peak velocity. This study aimed to compare the three approaches in patients with suspected HFpEF. Patients referred to right heart catheterization for suspected HFpEF were classified into low-, intermediate- and high-likelihood groups according to H2FPEF or HFA-PEFF scores. A diagnosis of HFpEF was confirmed by pulmonary capillary wedge pressure (PCWP) of ≥15 mm Hg according to the guidelines. In result, a total of 128 patients were included. Of these, 71 patients with PCWP ≥15 mm Hg and 57 patients with PCWP <15 mm Hg. Moderate correlations were observed between H2FPEF score, HFA-PEFF score, SVI/S′ and PCWP. The area under curve of SVI/S′ was 0.82 for diagnosis of HFpEF, compared with 0.67 for H2FPEF score and 0.75 for HFA-PEFF score by receiver-operating characteristics analysis. Combining SVI/S′ with diagnostic scores showed higher Youden index and accuracy than each score alone. Kaplan–Meier analysis reported that the high-likelihood group showed poorer outcomes regardless the method used for diagnosis. Among the contemporary tools for identifying HFpEF in this study, the combination of SVI/S′ with risk scores showed best diagnostic ability. Each of the strategies can determine rehospitalisation because of heart failure.
KW - HFA-PEFF score
KW - HFPEF score
KW - SVI/S′
KW - diagnosis
KW - heart failure with preserved ejection fraction
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85159717415&partnerID=8YFLogxK
U2 - 10.1111/1440-1681.13782
DO - 10.1111/1440-1681.13782
M3 - Article
C2 - 37203426
AN - SCOPUS:85159717415
SN - 0305-1870
VL - 50
SP - 677
EP - 687
JO - Clinical and Experimental Pharmacology and Physiology
JF - Clinical and Experimental Pharmacology and Physiology
IS - 8
ER -